[go: up one dir, main page]

WO2009140642A3 - Antagonistes tricycliques de récepteurs de prostaglandine d<sb>2</sb> - Google Patents

Antagonistes tricycliques de récepteurs de prostaglandine d<sb>2</sb> Download PDF

Info

Publication number
WO2009140642A3
WO2009140642A3 PCT/US2009/044219 US2009044219W WO2009140642A3 WO 2009140642 A3 WO2009140642 A3 WO 2009140642A3 US 2009044219 W US2009044219 W US 2009044219W WO 2009140642 A3 WO2009140642 A3 WO 2009140642A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptors
antagonists
pgd
prostaglandin
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/044219
Other languages
English (en)
Other versions
WO2009140642A2 (fr
Inventor
John Howard Hutchinson
Brian Andrew Stearns
Ryan Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amira Pharmaceuticals Inc
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/991,747 priority Critical patent/US20110112134A1/en
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Priority to JP2011509773A priority patent/JP2011521912A/ja
Priority to EP09747723A priority patent/EP2310392A4/fr
Publication of WO2009140642A2 publication Critical patent/WO2009140642A2/fr
Publication of WO2009140642A3 publication Critical patent/WO2009140642A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés qui sont des antagonistes de récepteurs de PGD2. Des compositions pharmaceutiques et des médicaments qui comprennent les composés décrits ici, qui sont des antagonistes de récepteurs de PGD2, sont également décrits. Des procédés sont également décrits pour l'utilisation de tels antagonistes de récepteurs de PGD2, seuls ou en combinaison avec d'autres composés, pour un traitement d'états ou de maladies respiratoires, cardiovasculaires et autres,  dépendantes de PGD2 ou à médiation par PGD2.
PCT/US2009/044219 2008-05-16 2009-05-15 Antagonistes tricycliques de récepteurs de prostaglandine d<sb>2</sb> Ceased WO2009140642A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/991,747 US20110112134A1 (en) 2008-05-16 2009-01-15 Tricyclic Antagonists of Prostaglandin D2 Receptors
JP2011509773A JP2011521912A (ja) 2008-05-16 2009-05-15 プロスタグランジンｄ２受容体の三環式アンタゴニスト
EP09747723A EP2310392A4 (fr) 2008-05-16 2009-05-15 Antagonistes tricycliques de récepteurs de prostaglandine d2

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5409308P 2008-05-16 2008-05-16
US61/054,093 2008-05-16
US10763808P 2008-10-22 2008-10-22
US61/107,638 2008-10-22

Publications (2)

Publication Number Publication Date
WO2009140642A2 WO2009140642A2 (fr) 2009-11-19
WO2009140642A3 true WO2009140642A3 (fr) 2010-03-11

Family

ID=41319367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044219 Ceased WO2009140642A2 (fr) 2008-05-16 2009-05-15 Antagonistes tricycliques de récepteurs de prostaglandine d<sb>2</sb>

Country Status (4)

Country Link
US (1) US20110112134A1 (fr)
EP (1) EP2310392A4 (fr)
JP (1) JP2011521912A (fr)
WO (1) WO2009140642A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2197438B1 (fr) 2007-10-10 2015-07-15 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Composés hétérocycliques comme antagonistes du récepteur crth2
WO2009061676A2 (fr) * 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonistes de récepteurs pgd2
US20100298368A1 (en) * 2007-11-06 2010-11-25 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
EP2300425A4 (fr) 2008-06-24 2012-03-21 Panmira Pharmaceuticals Llc Antagonistes de cycloalcaneýb¨indole de récepteurs de prostaglandine d2
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US20100173313A1 (en) * 2009-01-08 2010-07-08 Amira Pharmaceuticals, Inc. Biomarkers of inflammation
PT2401269E (pt) 2009-02-24 2014-03-11 Merck Canada Inc Derivados de indol como antagonistas de recetor crth2
EP2272977A1 (fr) * 2009-07-08 2011-01-12 Universite Libre De Bruxelles Procédé de diagnostic et kit pour la détection d'une variante lymphocyte du syndrome hyperéosinophilique
AR080703A1 (es) 2010-03-22 2012-05-02 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
PL2697223T3 (pl) 2011-04-14 2017-01-31 Actelion Pharmaceuticals Ltd. Pochodne kwasu 7-(heteroaryloamino)-6,7,8,9-tetrahydropirydo[1,2-a]indolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny D2
EP2912458B1 (fr) 2012-10-24 2018-07-18 NYU Winthrop Hospital Biomarqueurs non-invasifs pour identifier les sujets à risque d'accouchement prématuré
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
WO2014178891A1 (fr) 2013-04-30 2014-11-06 Otitopic Inc. Formulations de poudre sèche et procédés d'utilisation
EP3119779B1 (fr) 2014-03-17 2018-07-11 Idorsia Pharmaceuticals Ltd Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
ES2699379T3 (es) 2014-03-18 2019-02-11 Idorsia Pharmaceuticals Ltd Derivados de ácido azaindol acético y su uso como moduladores del receptor de prostaglandina D2
AU2016323262B2 (en) 2015-09-15 2020-11-19 Idorsia Pharmaceuticals Ltd Crystalline forms
EP3682250A4 (fr) 2017-09-13 2021-03-03 Progenity, Inc. Biomarqueurs de pré-éclampsie ainsi que systèmes et procédés associés
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN115919780A (zh) 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié
US20240002376A1 (en) * 2020-08-25 2024-01-04 City Of Hope Compositions and methods for g-protein-coupled receptor 44 detection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4549020A (en) * 1982-06-30 1985-10-22 Richter Gedeon Vegyeszeti Gyar Rt. Eburnane oxime ethers
WO1990000171A1 (fr) * 1988-06-28 1990-01-11 Roussel-Uclaf Nouveaux derives de la 20,21-dinoreburnamenine substitues en 15 par un groupement amine et leurs sels, leur procede de preparation et les intermediaires ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
DE4027278A1 (de) * 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
EP1383771A1 (fr) * 2001-04-20 2004-01-28 Vertex Pharmaceuticals Incorporated Derives de 9-deazaguanine utilises comme inhibiteurs de la gsk-3
DE60215000T2 (de) * 2001-05-23 2007-08-09 Merck Frosst Canada & Co, Kirkland Dihydropyrroloil[1,2-a]indol- und Tetrahydropyridol[1,2-a]indol-Derivate als Prostaglandin-D2-Rezeptor-Antagonisten
US7534897B2 (en) * 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
EP1558614B1 (fr) * 2002-10-30 2010-09-01 Merck Frosst Canada Ltd. Pyridopyrrolizine et derives de pyridoindolizine
PT1725553E (pt) * 2004-03-11 2008-07-16 Actelion Pharmaceuticals Ltd Derivados de tetra-hidropiridoindole
ES2443022T3 (es) * 2005-08-12 2014-02-17 Merck Frosst Canada Inc. Derivados de indol como antagonistas del receptor CRTH2
GB0518783D0 (en) * 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
KR101644170B1 (ko) * 2008-01-18 2016-08-01 옥사겐 리미티드 씨알티에이치2 길항제 활성을 갖는 화합물
GB2465062B (en) * 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4549020A (en) * 1982-06-30 1985-10-22 Richter Gedeon Vegyeszeti Gyar Rt. Eburnane oxime ethers
WO1990000171A1 (fr) * 1988-06-28 1990-01-11 Roussel-Uclaf Nouveaux derives de la 20,21-dinoreburnamenine substitues en 15 par un groupement amine et leurs sels, leur procede de preparation et les intermediaires ainsi obtenus, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
EP2310392A2 (fr) 2011-04-20
JP2011521912A (ja) 2011-07-28
EP2310392A4 (fr) 2011-08-24
WO2009140642A2 (fr) 2009-11-19
US20110112134A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
WO2009140642A3 (fr) Antagonistes tricycliques de récepteurs de prostaglandine d&lt;sb&gt;2&lt;/sb&gt;
WO2010003127A3 (fr) Antagonistes des récepteurs de la prostaglandine d&lt;sb&gt;2&lt;/sb&gt;
WO2009108720A3 (fr) Antagonistes des récepteurs d2 de la prostaglandine
WO2009145989A3 (fr) Antagonistes d’aminoalkylphényle de récepteurs de prostaglandine d&lt;sb&gt;2&lt;/sb&gt;
WO2010008864A3 (fr) Antagonistes de cycloalcane[b]indole de récepteurs de prostaglandine d2
WO2010037054A3 (fr) Antagonistes hétéroaryliques des récepteurs de prostaglandine d&lt;sb&gt;2&lt;/sb&gt;
WO2010054114A3 (fr) Antagonistes cycloalcane[b]azaindoles de récepteurs de la prostaglandine d2
WO2010042652A3 (fr) Antagonistes hétéroalkyl biphényle des récepteurs de la prostaglandine d2
WO2010057118A3 (fr) Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
WO2009102893A3 (fr) Composés diaryliques cycliques en tant qu&#39;antagonistes de récepteurs de prostaglandine d&lt;sb&gt;2&lt;/sb&gt;
WO2010039977A3 (fr) Antagonistes d&#39;hétéroaryle des récepteurs de la prostaglandine d2
WO2010085820A3 (fr) Composés tricycliques en tant qu&#39;antagonistes des récepteurs d2 de la prostaglandine
WO2010077882A3 (fr) Antagonistes des récepteurs d&#39;acide lysophosphatidique
GB2460597A (en) N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
WO2010008831A3 (fr) Composés et procédés pour moduler les récepteurs couplés à la protéine g
WO2010068775A3 (fr) Antagonistes d&#39;alcyne de récepteurs d&#39;acide lysophosphatidique
WO2010141761A3 (fr) Antagonistes polycycliques de récepteurs d&#39;acide lysophosphatidique
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l&#39;activité du récepteur cannabinoïde 1
WO2011041461A3 (fr) Composés polycycliques utiles en tant qu&#39;antagonistes du récepteur de l&#39;acide lysophosphatidique
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
WO2009061676A3 (fr) Antagonistes de récepteurs pgd2
WO2011041729A3 (fr) Composés utiles comme antagonistes du récepteur de l&#39;acide lysophosphatidique (lpa)
WO2011017350A3 (fr) Composés en tant qu&#39;antagonistes du récepteur de l&#39;acide lysophosphatidique
WO2006047516A3 (fr) Composes et compositions servant d&#39;inhibiteurs d&#39;activite de recepteur cannabinoide de type 1
WO2007051062A3 (fr) Dihydropyridines substituees et leurs methodes d&#39;utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09747723

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011509773

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009747723

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12991747

Country of ref document: US